Regeneron Q3 revenue up 11% to $3.72B; GAAP EPS $11.54; Dupixent sales +23%

REGENERON PHARMACEUTICALS, INC.

2024-Q3 EPS reported $30.23 revenue$10,412,800,000

Revenue $3.72B (+11% YoY); GAAP net income $1.34B, diluted EPS $11.54 (up 30%).
Non-GAAP diluted EPS $12.46 (up 8%); includes $0.43 unfavorable IPR&D charge.
Dupixent global net sales $3.82B (+23%, recorded by Sanofi); EYLEA HD+EYLEA US $1.54B (+3%).
FDA approved Dupixent for COPD in Sept. 2024; positive Phase 3 data for CSU and bullous pemphigoid.
FY 2024 guidance updated: GAAP R&D $5.055-5.145B, SG&A $2.93-3.02B; share repurchases $738M in Q3.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.